Draft 2016 Vascular

Total Page:16

File Type:pdf, Size:1020Kb

Draft 2016 Vascular 2016 Cordis® Cardiac & Vascular Procedures Reimbursement Guide ® Table of Contents Description Page Hospital Inpatient Issues 2 Hospital Inpatient Coding 4 Hospital Inpatient Reimbursement 9 Hospital Outpatient Issues 13 Hospital Outpatient Reimbursement 15 Ambulatory Surgery Center and Independent Diagnostic Testing Facility Issues 20 Physician Reimbursement Issues 24 Bundling – NCCI and OCE Issues 25 CPT® Coding Updates in Recent Years 26 Modifiers 31 Disclaimer – The information contained in this guide has been compiled by a third-party organization from published sources and is provided for use as a reference for healthcare provider. The information is to the best of our knowledge true and accurate at the time of publication and may be subject to change without notice as a result of changing laws, regulations, local policies and rules. Healthcare providers are ultimately responsible for determining appropriate practices for services provided, procedures performed, and reimbursement sought including, but not limited to, medical necessity determination and documentation requirements, coding, coverage policy, billing, and payment for individual patients. Providers should consult each payor organization with regard to local reimbursement policies and requirements for billing. The information contained in this document is provided for information purposes only and represents no statement, promise or guarantee by Cordis Corporation concerning levels of reimbursement, payment, or charge. Similarly, all codes are provided for information purposes only and represent no statement, promise or guarantee by Cordis Corporation that these codes will be appropriate for any procedure using Cordis® products or that reimbursement will be made. It is important to research coverage and payment for procedures on a payer-specific basis as coverage policies and guidelines vary by payer. The information in this guide is broad-based and references many different procedures and types of devices. Such a broad discussion is not intended to suggest or imply that Cordis® offers products for every use or procedure discussed and the FDA-approved labeling for all products may not be consistent with the information in this guide. As always, please refer to the package insert for a complete description of indications and contraindications for any medical device type mentioned in these materials prior to use. 2 HOSPITAL INPATIENT ISSUES Introduction to the 2016 Hospital Inpatient Prospective Payment System (IPPS) Final Rule On July 31, 2015, the Centers for Medicare & Medicaid Services (CMS) issued the final rule for acute inpatient hospital services, detailing changes to Medicare payment rates and policies for fiscal year 2016. The final rule appeared in the August 17th Federal Register and will be effective for discharges on or after October 1, 2015.1 Medicare previously adopted the Medicare Severity Diagnosis Related Group (MS-DRG) system to better account for patient severity of illness, expanding the number of payment groups from 538 to 745; there are now 758 MS-DRGs. The intent of the MS-DRG system is to more accurately stratify groups of Medicare patients with varying levels of severity than the prior DRG system by better aligning payments with the anticipated costs of care, and are assigned based upon the presence or absence of specific diagnosis codes indicating complications or comorbidities (CCs) and/or major complications or comorbidities (MCCs). ‘Complications’ include all conditions that develop after inpatient admission which affect treatment and/or length of stay; ‘cormorbidities’ are conditions which pre-exist at the time of admission. While most commercial insurers are also following MS-DRGs, some may utilize other reimbursement methods.2 The Final Rule includes policies that continue an increasing shift of Medicare payments from volume to value. Among other key changes in the IPPS for FY 2016 are the following:2 1) FY 2016 Inpatient Hospital Update: The final rule updates IPPS payment rates by 1.7% for hospitals that successfully participate in the Hospital Inpatient Quality Reporting (IQR) Program AND are meaningful users of EHR, which reflects a market basket increase of 2.4% reduced by several adjustment factors. 2) Quality Measure Reporting for 2016 Updates: Under the Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU), in effect since 2004, hospitals that choose not to participate or fail to meet criteria for successful reporting in a given year received the annual payment update (APU) reduced by 2.0%. The 2016 final rule adds 7 new measures: 4 for the FY 2018 payment determination, and 3 for the FY 2019 payment determination. 3) Hospital Readmissions Reduction Program: The Affordable Care Act established this program, under which payments to certain hospitals will be reduced to account for excess readmissions. Two new measures bring the total to five: acute myocardial infarction (AMI) or heart attack, heart failure, pneumonia, hip/knee arthroplasty, and chronic obstructive pulmonary disease. 4) Other Payment Policy Updates: The Final Rule also addresses operational details regarding: • The Hospital Value-Based Purchasing (VBP) Program; • Admissions and Medical Review Criteria for Inpatient Services; • Clarifications to the “Two Midnight Rule” and Part B Rebilling for Inpatient Services in Hospitals later determined to be outpatient stays; • Medicare Disproportionate Share Hospitals (DSH) payments; and • Direct Graduate Medical Education (DGME). Expiring provisions include: the Medicare-Dependent Hospital (MDH) Program, and Affordable Care Act changes to the Low-Volume Hospital Payment Adjustment. 1 October 1, 2015 through September 30, 2016. 2 Centers for Medicare and Medicaid Services Fact Sheet: FY 2016 Final Inpatient and Long-term Care Hospital Policy and Payment Changes (CMS-1632-F); July 31, 2015; http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-Sheets. 3 5) Quality Reporting Programs: The Affordable Care Act called for CMS to create new quality reporting programs for two types of hospitals that are exempt from payment under the IPPS. The Hospital IQR Program grew out of the Hospital Quality Initiative developed by CMS in consultation with hospital groups. By statute, annual payment updates for hospitals that do not participate successfully in the Hospital IQR program are reduced by 2.0 percentage points. Beginning with fiscal year 2015, hospitals that do not participate will lose one-quarter of the percentage increase in their payment updates. Since the implementation of this financial penalty, hospital participation has increased to well over 99 percent. For the FY 2016 payment determination and subsequent years, CMS will remove six chart abstracted measures and one structural measure, while suspending one chart-abstracted measure and adopting five new claims-based measures: (1) 30-day risk-standardized COPD Readmission; (2) 30-day risk standardized COPD mortality; (3) 30-day risk standardized stroke readmission; (4) 30-day risk standardized stroke mortality; and (5) AMI payment per episode of care. CMS also finalized a proposal to reduce the number of records used for Hospital Acquired Infection (HAI) validation from 48 records per year to 36 records per year beginning with the FY 2015 payment determination, and to provide hospitals with the option to transmit secure electronic versions of medical information to meet validation requirements. 6) Hospital Acquired Conditions Reduction Program: The FY 2014 hospital payment rule finalized the general framework for the Hospital-Acquired Condition (HAC) Reduction Program. Section 3008 of the Affordable Care Act requires CMS to establish a program for IPPS hospitals to improve patient safety, by imposing financial penalties on hospitals that perform poorly with regard to hospital-acquired conditions. HACs are conditions that patients did not have when they were admitted to the hospital, but which developed during the hospital stay. Under the HAC Reduction Program, hospitals that rank in the lowest-performing quartile of hospital-acquired conditions will be paid 99 percent of what otherwise would have been paid under IPPS, beginning in FY 2015. The rule finalizes the quality measures and the scoring methodology to determine this quartile, as well as the process hospitals use to review and correct their data. In the first year of the program, FY 2015, CMS used measures that are part of the IQR program. The HAC measures consist of two domains of measure sets. • Domain 1 includes the Agency for Health Care Research and Quality (AHRQ) composite PSI #90. This measure includes the following indicators: Pressure ulcer rate (PSI 3); Iatrogenic pneumothorax rate (PSI 6); Central venous catheter-related blood stream infection rate (PSI 7); Postoperative hip fracture rate (PSI 8); Postoperative pulmonary embolism (PE) or deep vein thrombosis rate (DVT) (PSI 12); Postoperative sepsis rate (PSI 13); Wound dehiscence rate (PSI 14); and Accidental puncture and laceration rate (PSI 15). • Domain 2 measures consist of two healthcare-associated infection measures developed by the Centers for Disease Control and Prevention’s (CDC) National Health Safety Network: Central Line-Associated Blood Stream Infection and Catheter-Associated Urinary Tract Infection. Hospitals will be given a score for each measure within the two domains. A domain score will be calculated—with Domain 1 weighted at 35 percent and Domain 2 weighted at 65 percent—to determine a total score under the program.
Recommended publications
  • Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Eur J Vasc Endovasc Surg 16, 254-258 (1998) ENDOVASCULAR AND SURGICAL TECHNIQUES Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique M. S. Whiteley 1, T. R. Magee 1, E. P. H. Torrie 2 and R. B. Galland* Department of ~Surgery and 2Radiology, Royal Berkshire Hospital, London Road, Reading, U.K. Objectives: To describe our experience of a modified technique for carrying out remote endarterectomy for superficial femoral artery occlusive disease. Methods: A 4-French arterial dilator is inserted using a Smart needle into the popliteal artery below the occlusion. A remote endarterectomy is carried out through an arteriotomy in the proximal superficial femoral artery. The atheroma is cut distal to the lower extent of disease using a Moll ring cutter. The lower flap of atheroma is secured with an intraluminaI stent inserted from the arteriotomy in the superficial femoral artery. The arteriotomy is extended into the common femoral artery and closed with a vein patch. Results: The procedure was completed in 21 of 26 limbs. In 18 cases the superficial femoral artery remained patent at 30 days. Of the 21 cases all but four stayed in hospital for one night. A successful femoropopliteal bypass was carried out in the five patients in whom the procedure was not completed. Conclusion: Insertion of the dilator into the popliteal artery distal to the occlusion before carrying out the remote endarterectomy has two advantages. Firstly, the stent insertion is carried out in the correct plane and prevents dissection of the distal cut atheroma when attempting to pass the guidewire from above.
    [Show full text]
  • Coronary Artery Perforation
    Published online: 2019-09-20 THIEME 110 InterventionalCoronary Artery Rounds Perforation Deb et al. Coronary Artery Perforation Tripti Deb1 Jyotsna Maddury2 Prasant Kr. Sahoo3 1Department of Interventional Cardiology, Apollo Hospitals, Address for correspondence Jyotsna Maddury, MD, DM, FACC, Hyderabad, Telangana, India Department of Cardiology, Nizam’s Institute of Medical Sciences 2Department of Cardiology, Nizam’s Institute of Medical Sciences (NIMS), Punjagutta, Hyderabad, Telangana 500082, India (NIMS), Punjagutta, Hyderabad, India (e-mail: [email protected]). 3Department of Interventional Cardiology, Apollo Hospitals, Bhubaneswar, Odisha, India Ind J Car Dis Wom 2019;4:110–120 Abstract Percutaneous coronary intervention (PCI) is considered as the standard treatment of obstructive coronary artery disease in indicated patients. Even though PCI gives symp- Keywords tomatic angina improvement, but associated with serious complications like coronary ► coronary artery artery perforation (CAP), the incidence is quite low. With the more complex lesions for perforation successful angioplasty, different devices are required, which in turn increase the inci- ► percutaneous coro- dence of CAP in these patients. Here we review the classification, incidence, pathogen- nary intervention esis, clinical sequela, risk factors, predictors, and management of CAP in the current ► coronary artery era due to PCI. perforation ► management of coro- nary perfusion Introduction Consequences of Coronary Artery Perforation Percutaneous coronary intervention (PCI) for obstructive coronary artery diseases is accepted and has standardized Consequences of CAP depend on the location and severity. procedure with minimal complication rates, including iat- Location wise, if CAP occurs to the right or left ventricle, if not rogenic coronary artery perforation (CAP). Although angio- massive, then usually no immediate clinical consequences graphically significant coronary artery dissection is known occur.
    [Show full text]
  • Targeting Endothelial Kruppel-Like Factor 2 (KLF2) in Arteriovenous
    Targeting Endothelial Krüppel-like Factor 2 (KLF2) in Arteriovenous Fistula Maturation Failure A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Biomedical Engineering Program Department of Biomedical Engineering College of Engineering and Applied Science 2018 by Keith Louis Saum B.S., Wright State University, 2012 Dissertation Committee: Albert Phillip Owens III, Ph.D. (Committee Chair) Begona Campos-Naciff, Ph.D Christy Holland, Ph.D. Daria Narmoneva, Ph.D. Prabir Roy-Chaudhury, M.D., Ph.D Charuhas Thakar, M.D. Abstract The arteriovenous fistula (AVF) is the preferred form of vascular access for hemodialysis. However, 25-60% of AVFs fail to mature to a state suitable for clinical use, resulting in significant morbidity, mortality, and cost for end-stage renal disease (ESRD) patients. AVF maturation failure is recognized to result from changes in local hemodynamics following fistula creation which lead to venous stenosis and thrombosis. In particular, abnormal wall shear stress (WSS) is thought to be a key stimulus which alters endothelial function and promotes AVF failure. In recent years, the transcription factor Krüppel-like factor-2 (KLF2) has emerged as a key regulator of endothelial function, and reduced KLF2 expression has been shown to correlate with disturbed WSS and AVF failure. Given KLF2’s importance in regulating endothelial function, the objective of this dissertation was to investigate how KLF2 expression is regulated by the hemodynamic and uremic stimuli within AVFs and determine if loss of endothelial KLF2 is responsible for impaired endothelial function.
    [Show full text]
  • 3Rd Quarter 2001 Bulletin
    In This Issue... Promoting Colorectal Cancer Screening Important Information and Documentaion on Promoting the Prevention of Colorectal Cancer ....................................................................................................... 9 Intestinal and Multi-Visceral Transplantation Coverage Guidelines and Requirements for Approval of Transplantation Facilities12 Expanded Coverage of Positron Emission Tomography Scans New HCPCS Codes and Coverage Guidelines Effective July 1, 2001 ..................... 14 Skilled Nursing Facility Consolidated Billing Clarification on HCPCS Coding Update and Part B Fee Schedule Services .......... 22 Final Medical Review Policies 29540, 33282, 67221, 70450, 76090, 76092, 82947, 86353, 93922, C1300, C1305, J0207, and J9293 ......................................................................................... 31 Outpatient Prospective Payment System Bulletin Devices Eligible for Transitional Pass-Through Payments, New Categories and Crosswalk C-codes to Be Used in Coding Devices Eligible for Transitional Pass-Through Payments ............................................................................................ 68 Features From the Medical Director 3 he Medicare A Bulletin Administrative 4 Tshould be shared with all General Information 5 health care practitioners and managerial members of the General Coverage 12 provider/supplier staff. Hospital Services 17 Publications issued after End Stage Renal Disease 19 October 1, 1997, are available at no-cost from our provider Skilled Nursing Facility
    [Show full text]
  • ICD~10~PCS Complete Code Set Procedural Coding System Sample
    ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00
    [Show full text]
  • Ventricular Long Axis Function: Amplitudes and Timings
    Umeå University Medical Dissertations New Series No 895 - ISSN 0346-6612 _______________________________________________________________ From the Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden Ventricular Long Axis Function: Amplitudes and Timings Echocardiographic Studies in Health and Disease Frederick Bukachi Umeå 2004 © Copyright: Frederick Bukachi ISBN 91-7305-661-8 Printed in Sweden by Solfjädern offset AB Umeå, 2004 To my family Frida, Anthony, Arnold and Maria Time brings wisdom to the mind and healing to the heart. Anonymous Table of contents Table of contents................................................................................................................. 1 Abstract ................ ............................................................................................................. 3 List of original studies ........................................................................................................4 Abbreviations...................................................................................................................... 5 1. Introduction............................................................................................................. 6 2. Ventricular long axis ............................................................................................... 6 2.1. General overview and historical perspective................................................ 6 2.2. Anatomy of long axis ..................................................................................
    [Show full text]
  • Transpulmonary Closure of Giant Persistent Ductus Arteriosus Under Cardiopulmonary Bypass and Normothermic Cardioplegia
    Published online: 2019-11-25 THIEME 36 TranspulmonaryPoint of Technique Closure of Giant Persistent Ductus Arteriosus Chowdhury et al. Transpulmonary Closure of Giant Persistent Ductus Arteriosus under Cardiopulmonary Bypass and Normothermic Cardioplegia Ujjwal K. Chowdhury1 Sukhjeet Singh1 Niwin George1 Lakshmi Kumari Sankhyan1 Poonam Malhotra Kapoor2 1Department of Cardiothoracic and Vascular Surgery, All India Address for correspondence Ujjwal K. Chowdhury, MCh, Institute of Medical Sciences, New Delhi, India Department of Cardiothoracic and Vascular Surgery, All 2Department of Cardiac Anaesthesia, All India Institute of Medical India Institute of Medical Sciences, New Delhi 110029, India Sciences, New Delhi, India (e-mail: [email protected]). J Card Crit Care TSS 2020;3:36–38 Abstract A 25-year-old female patient with a giant, short, calcified, hypertensive, window duc- tus arteriosus underwent successful closure via transpulmonary approach under nor- Keywords mothermic cardiopulmonary bypass without circulatory arrest using a Foley catheter ► giant ductus for temporary occlusion. arteriosus ► adult ductus ► cardiopulmonary bypass ► transpulmonary closure ► calcified ductus Introduction chylothorax, or recanalization. Postoperative computerized tomographic angiography revealed complete ductal inter‑ Despite 80 years of experience, correction of persistent duc‑ ruption with no residual shunt or ductal aneurysm (►Fig. 3). tus arteriosus remains a surgical challenge in the subset of 1. Primary median sternotomy is performed. patients
    [Show full text]
  • TAXUS™ Express 2 ™ Paclitaxel-Eluting
    TAXU S ® Express 2® Paclitaxel-Eluting Coronary Stent System Patient Information Guide Table of Contents Notes Coronary Artery Disease . 2 Who is at Risk? . .3 Diagnosis of Coronary Artery Disease . 3 Treatment of Coronary Artery Disease . 3 Angioplasty . 4 Coronary Artery Stents . 4 Restenosis . 5 Your Drug-Eluting Stent, the TAXUS ® Express 2® Paclitaxel-Eluting Coronary Stent System . 7 Drug-Eluting Stents . 7 The Express ® Stent Platform for the TAXUS ® Express ® Stent . 7 The Polymer Coating on the TAXUS Express Stent . 7 The Drug that is Released from the TAXUS Express Stent . 8 When should the TAXUS Express Stent NOT be Used . 8 What are the Risks & Potential Benefits of Treatment with the TAXUS Express Stent? . 9 Alternative Practices and Procedures . 11 The Angioplasty Procedure . 12 Preparation for the Procedure . 12 Angioplasty and Stent Placement Procedure . 12 Post-Treatment . 13 After the Procedure . 13 Activity . 14 Medications . 14 Follow-Up Examinations . 15 Magnetic Resonance Imaging (MRI) . 15 Frequently Asked Questions . 16 Glossary . 17 Patient Information Card . Inside Back Cover 1 Notes Coronary Artery Disease Coronary Artery Disease (CAD) is usually caused by atherosclerosis, and affects the coronary arteries that surround the heart. These coronary arteries supply blood with oxygen and other nutrients to the heart muscle to make it function properly. CAD occurs when the inner walls of the coronary arteries thicken due to a buildup of cholesterol, fatty deposits, calcium, and other elements. This material is known as plaque. As plaque develops, the vessel narrows. When the vessel narrows (for example with physical exertion or mental stress), Aorta blood flow through the vessel is reduced so less oxygen and Right Left other nutrients reach Coronary Coronary the heart muscle.
    [Show full text]
  • Clinical Appropriateness Guidelines: Percutaneous Coronary Intervention
    Clinical Appropriateness Guidelines: Percutaneous Coronary Intervention Appropriate Use Criteria Effective Date: January 2, 2018 Proprietary Date of Origin: 08/27/2015 Last revised: 08/01/2017 Last reviewed: 09/07/2017 8600 W Bryn Mawr Avenue South Tower - Suite 800 Chicago, IL 60631 P. 773.864.4600 Copyright © 2018. AIM Specialty Health. All Rights Reserved www.aimspecialtyhealth.com Table of Contents Description and Application of the Guidelines ........................................................................3 Percutaneous Coronary Intervention .......................................................................................4 Table of Contents | Copyright © 2018. AIM Specialty Health. All Rights Reserved. 2 Description and Application of the Guidelines AIM’s Clinical Appropriateness Guidelines (hereinafter “AIM’s Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. As used by AIM, the Guidelines establish objective and evidence-based, where possible, criteria for medical necessity determinations. In the process, multiple functions are accomplished: ● To establish criteria for when services are medically necessary ● To assist the practitioner as an educational tool ● To encourage standardization of medical practice patterns ● To curtail the performance of inappropriate and/or duplicate services ● To advocate for patient safety concerns ● To enhance the quality of healthcare ● To promote the most efficient and cost-effective use of services AIM’s guideline development process complies with applicable accreditation standards, including the requirement that the Guidelines be developed with involvement from appropriate providers with current clinical expertise relevant to the Guidelines under review and be based on the most up to date clinical principles and best practices. Relevant citations are included in the “References” section attached to each Guideline.
    [Show full text]
  • Everolimus Eluting Coronary Stent System
    Everolimus Eluting Coronary Stent System Patient Information Guide Table of Contents Coronary Artery Disease (CAD) ........................5 Your Drug-Eluting Stent Procedure ................19 Your Heart ........................................................5 How Do I Prepare for My Procedure? ...........19 What is CAD? ..................................................5 Your Drug-Eluting Stent Placement What are the Symptoms of CAD? ...................5 Procedure ......................................................19 What are the Risk Factors of CAD? ................6 Immediately after Procedure .........................22 How Can My Doctor Tell if I Have CAD? .........7 Take All Medications as Instructed ................22 Follow-up Care ..............................................23 Your Treatment Options .....................................8 Keep Your ID Card Handy .............................23 Surgery .............................................................9 Angioplasty ......................................................9 Preventing CAD ................................................24 Coronary Artery Stents ..................................10 Frequently Asked Questions ...........................25 Drug-Eluting Stents (DES) ...............................11 Definition of Medical Terms ............................26 XIENCE Family of Coronary Stents ................12 Contraindications ...........................................13 Potential Adverse Events Associated with the XIENCE Family of Coronary Stents ..........13
    [Show full text]
  • Pericardial Bleeding Following Covered Stent Thrombosis: Sharp Blade on Both Sides
    CASE REPORT Acta Medica Alanya 2018;2(3): 210-214 OLGU SUNUMU DOI: 10.30565/ medalanya.421746 Pericardial Bleeding Following Covered Stent Thrombosis: Sharp Blade on Both Sides Kaplı Stent Trombozu Sonrası Perikardiyal Kanama: İki Ucu Keskin Bıçak Ali Çoner1*, Davran Çiçek1, Sinan Akıncı1, Tonguç Saba2, Haldun Müderrisoğlu3 1.Department of Cardiology, Başkent University Alanya Education and Research Center, Alanya, Turkey 2.Department of Cardiovascular Surgery, Başkent University, Education and Research Center, Alanya, Turkey 3.Department of Cardiology, Başkent University Hospital, Ankara, Turkey ABSTRACT ÖZ Advancements in coronary stent technology encourage interventional cardiologists Koroner stent alanındaki teknolojik gelişmeler girişimsel kardiyologları daha kom- in performing more complex, percutaneous interventions. Coronary perforation is pleks perkütan girişimler gerçekleştirme konusunda cesaretlendirmektedir. Koroner a lethal complication of percutaneous coronary artery interventions and should be perforasyon perkütan koroner arter girişimleri esnasında görülebilen ölümcül bir managed within seconds to minutes. Despite technological advancements, coronary komplikasyondur ve saniyeler veya dakikalar içerisinde müdahale edilmelidir. perforation incidence has not declined over the years. This consistent incidence of Geçen yıllar içerisinde teknolojik gelişmeler olmasına karşın koroner perforasyon coronary perforation may be related to increased number of complex, percutaneous sıklığı azalmamıştır. Koroner perforasyon sıklığında
    [Show full text]
  • Electrocardiogram-Gated Intravascular Ultrasound Image
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository 436 JACC Vol. 30, No. 2 August 1997:436–43 INTERVENTIONAL CARDIOLOGY Electrocardiogram-Gated Intravascular Ultrasound Image Acquisition After Coronary Stent Deployment Facilitates On-Line Three-Dimensional Reconstruction and Automated Lumen Quantification CLEMENS VON BIRGELEN, MD,* GARY S. MINTZ, MD, FACC,† ANTONINO NICOSIA, MD, DAVID P. FOLEY, MB, MRCPI, PHD, WIM J. VAN DER GIESSEN, MD, PHD, NICO BRUINING, BSC, SERGEI G. AIRIIAN, MD, JOS R. T. C. ROELANDT, MD, PHD, FACC, PIM J. DE FEYTER, MD, PHD, FACC, PATRICK W. SERRUYS, MD, PHD, FACC Rotterdam, The Netherlands and Washington, D.C. Objectives. This study evaluates the feasibility, reliability and correlated closely (r >2 0.95), and the minimal stent lumen differed reproducibility of electrocardiogram (ECG)-gated intravascular only minimally (8.6 6 2.8 mm2 vs. 8.5 6 2.8 mm2,p5NS). The ultrasound (IVUS) image acquisition during automated trans- conventional analysis significantly overestimated the minimal ducer withdrawal and automated three-dimensional (3D) bound- stent lumen (9.0 6 2.7 mm2, p < 0.005) in comparison with results ary detection for assessing on-line the result of coronary stenting. of both 3D analyses. Fourteen stents (41%) failed to meet the Background. Systolic-diastolic image artifacts frequently limit criteria by both 3D analyses, all of these not reaching optimal the clinical applicability of such automated analysis systems. expansion, but only 7 (21%) were detected by conventional anal- Methods. In 30 patients, after successful angiography-guided ysis (p < 0.02).
    [Show full text]